[Click eStock] "Crystal, Corporate Value Expected to Rise Due to Ivaltinosta"

[Asia Economy Reporter Hyunseok Yoo] Korea Investment & Securities analyzed on the 7th that the value of Crystal's pipeline Ivaltinostat is expected to be highlighted. No investment opinion or target price was presented.

Ivaltinostat is an HDAC inhibitor with a mechanism that suppresses the proliferation of cancer cells. Compared to competing drugs, it targets a greater variety of HDAC enzymes and also has excellent selective inhibitory ability. According to Korea Investment & Securities, it is Crystal's core pipeline that has received orphan drug designation for both pancreatic cancer and liver cancer in the United States and Korea.

Seungyoon Jeon, a researcher at Korea Investment & Securities, explained, "The value of the Ivaltinostat pipeline is expected to be further highlighted as it expands to various indications such as liver cancer, MDS, and fibrosis, and as late-stage clinical trials for pancreatic cancer progress. The key differentiator is its outstanding ability to regulate the tumor microenvironment and improve immune response."

He added, "This is a point where synergy with PD1 immune checkpoint inhibitors can be expected, and the company plans to start full-scale clinical trials targeting liver cancer patients from next year. Since there are numerous Phase 1 safety data, the goal is to enter Phase 2 clinical trials in the US within the first half of next year."

He also stated, "The company plans to establish a subsidiary in the US to develop it as a treatment for fibrosis. Given the potential for conditional approval, entry into late-stage clinical trials, global technology transfer possibilities, and indication expansion, we recommend continued interest in Crystal as mid- to long-term corporate value is expected to rise."

This content was produced with the assistance of AI translation services.